drugsTreatmentPhase 3

Pelabresib

Pelabresib is an experimental small-molecule drug from Novartis Pharmaceuticals in phase 3 trials, with its target not yet stated publicly.

Pelabresib (CPI-0610) is a small-molecule drug developed by Novartis Pharmaceuticals. The sponsor describes its target as BET (bromodomain and extraterminal protein), which OnCo does not yet have a target page for. The sponsor states: A small-molecule BET protein inhibitor. ClinicalTrials.gov describes the intervention as: Small molecule inhibitor of bromodomain and extraterminal (BET) protein. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06401356 (An Extension Study for Patients Previously Enrolled in Studies With Pelabresib). The largest, NCT06401356, plans to enrol 50 participants with primary completion expected 2027-06-02. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.

How targeted therapy works, step by step · animated schematic, not to scale; chosen from the modality "small molecule"

Targeted Therapy →

Modality

small molecule

Mechanism

A small-molecule BET protein inhibitor.

Brand / code

CPI-0610

Trials

top

Trials recruiting now

Recruiting trials near you · live from ClinicalTrials.gov

Pelabresib

intervention: Pelabresib

Open on ClinicalTrials.gov →

within

Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.